Blog

Antibody-drug conjugates (ADCs) are one of the fastest-growing classes of therapies in precision oncology. In this guide to adc drugs by target, we provide a comprehensive and updated overview of approved antibody-drug conjugates, together with…

As global drug patents continue to expire, the China Generic Drug Market Trends 2026 indicate that the industry is entering a new cycle of competition and opportunity. Around 2026, the Chinese pharmaceutical industry is approaching…

Liver cancer is one of the most serious and life-threatening cancers worldwide. According to the International Agency for Research on Cancer (IARC), liver cancer remains one of the leading causes of cancer-related deaths globally. As…

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and remains a leading cause of cancer incidence and mortality, according to the World Health Organization and the National Cancer Institute. In recent…

Against the backdrop of the ongoing restructuring of the global pharmaceutical supply chain, China is steadily emerging as a key pillar in the international drug distribution system, with china pharmaceutical wholesaler solutions playing an increasingly…

In the context of increasingly stringent global pharmaceutical regulations, choosing a licensed Pharmaceutical Distributor in Hong Kong with verified wholesale and export qualifications means selecting a long-term partner with regulatory compliance, cross-border execution capabilities, and…

In 1852, French physician Duchenne described boys with progressive muscle weakness whose enlarged calves were replaced by fat and fibrous tissue, leading to death from respiratory or cardiac complications in adolescence or early adulthood. The…

In today’s increasingly competitive global pharmaceutical landscape, choosing a reputable pharmaceutical wholesaler has become a critical strategic decision for pharmaceutical companies, healthcare institutions, and medical traders seeking sustainable long-term growth. A reliable partner not only…

Lung cancer remains the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Thanks to advances in molecular pathology, its treatment has shifted from traditional chemotherapy…

Before the advent of targeted therapy, ALK-positive advanced non-small cell lung cancer (NSCLC) typically progressed rapidly, with a high incidence of brain metastases and limited median survival. Treatment strategies primarily relied on passive control through…

Epidermal growth factor receptor EGFR–targeted drugs represent a cornerstone in the treatment of advanced non–small cell lung cancer (NSCLC) harboring EGFR gene mutations. EGFR mutations are a major category of lung cancer biomarkers. NSCLC is…

In recent years, rare disease treatment has rapidly risen from a niche medical issue to one of the most active core areas of global pharmaceutical innovation. Advances in gene sequencing technology, breakthroughs in cell and…